Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating on the biotechnology company’s stock.

A number of other equities analysts have also commented on the stock. HC Wainwright reduced their target price on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Guggenheim dropped their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research report on Wednesday, March 26th. Scotiabank decreased their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a report on Friday, March 21st. Jones Trading cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, April 11th. Finally, Wells Fargo & Company lowered their target price on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a report on Friday, March 21st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1.83.

Adaptimmune Therapeutics Price Performance

Shares of ADAP stock opened at $0.29 on Thursday. The stock has a 50 day moving average price of $0.30 and a 200 day moving average price of $0.52. The firm has a market capitalization of $75.27 million, a P/E ratio of -1.33 and a beta of 2.86. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The company had revenue of $3.22 million for the quarter, compared to analysts’ expectations of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. As a group, sell-side analysts predict that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Institutional Trading of Adaptimmune Therapeutics

Several large investors have recently added to or reduced their stakes in ADAP. Jane Street Group LLC lifted its holdings in shares of Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares during the period. Virtu Financial LLC lifted its stake in Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 21,769 shares during the period. LPL Financial LLC increased its stake in shares of Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 94,623 shares during the period. Invesco Ltd. raised its holdings in shares of Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 28,526 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Adaptimmune Therapeutics by 52.5% during the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock valued at $1,361,000 after purchasing an additional 869,949 shares during the period. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.